| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 64 | 2025 | 897 | 9.100 |
Why?
|
| Mohs Surgery | 10 | 2025 | 38 | 2.540 |
Why?
|
| Melanoma | 22 | 2024 | 954 | 2.180 |
Why?
|
| Dermatologic Surgical Procedures | 8 | 2021 | 39 | 2.120 |
Why?
|
| Carcinoma, Basal Cell | 18 | 2024 | 69 | 2.090 |
Why?
|
| Aminoquinolines | 6 | 2010 | 34 | 1.310 |
Why?
|
| Skin Diseases | 9 | 2024 | 136 | 1.180 |
Why?
|
| Anesthesia, Local | 2 | 2025 | 38 | 1.080 |
Why?
|
| Skin | 11 | 2024 | 527 | 1.080 |
Why?
|
| Suture Techniques | 6 | 2021 | 189 | 1.040 |
Why?
|
| Psoriasis | 3 | 2024 | 48 | 1.030 |
Why?
|
| Anesthetics, Local | 2 | 2025 | 86 | 1.020 |
Why?
|
| Nose Neoplasms | 4 | 2022 | 32 | 1.010 |
Why?
|
| Pain Perception | 1 | 2025 | 5 | 0.930 |
Why?
|
| Acute Pain | 1 | 2025 | 17 | 0.910 |
Why?
|
| Head and Neck Neoplasms | 3 | 2020 | 623 | 0.900 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2024 | 15 | 0.880 |
Why?
|
| Hemochromatosis | 1 | 2024 | 38 | 0.830 |
Why?
|
| Scalp | 5 | 2020 | 57 | 0.810 |
Why?
|
| Surgical Flaps | 5 | 2022 | 189 | 0.790 |
Why?
|
| Hidrocystoma | 2 | 2020 | 4 | 0.780 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2020 | 16 | 0.770 |
Why?
|
| Adjuvants, Immunologic | 5 | 2007 | 392 | 0.750 |
Why?
|
| Apocrine Glands | 2 | 2020 | 5 | 0.710 |
Why?
|
| Biopsy | 13 | 2018 | 1288 | 0.710 |
Why?
|
| Carcinoma, Squamous Cell | 12 | 2024 | 768 | 0.700 |
Why?
|
| Humans | 115 | 2025 | 132247 | 0.690 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 414 | 0.660 |
Why?
|
| Patient Positioning | 1 | 2021 | 56 | 0.660 |
Why?
|
| Surgeons | 1 | 2024 | 286 | 0.620 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 899 | 0.610 |
Why?
|
| Skin Physiological Phenomena | 1 | 2018 | 17 | 0.600 |
Why?
|
| Leiomyosarcoma | 2 | 2010 | 29 | 0.590 |
Why?
|
| Nails | 3 | 2024 | 21 | 0.580 |
Why?
|
| Tinea | 2 | 2018 | 6 | 0.580 |
Why?
|
| Neck | 2 | 2014 | 142 | 0.570 |
Why?
|
| Diagnosis, Differential | 20 | 2021 | 1966 | 0.550 |
Why?
|
| Dermatology | 6 | 2008 | 30 | 0.540 |
Why?
|
| Ultraviolet Rays | 6 | 2024 | 198 | 0.530 |
Why?
|
| Immunologic Factors | 2 | 2010 | 185 | 0.530 |
Why?
|
| Carcinoid Tumor | 1 | 2017 | 24 | 0.530 |
Why?
|
| Middle Aged | 36 | 2025 | 29021 | 0.510 |
Why?
|
| Male | 51 | 2025 | 65014 | 0.510 |
Why?
|
| Hospitalization | 1 | 2024 | 1902 | 0.470 |
Why?
|
| Fluorouracil | 3 | 2010 | 138 | 0.470 |
Why?
|
| Space Flight | 1 | 2018 | 165 | 0.460 |
Why?
|
| Aged, 80 and over | 12 | 2025 | 7138 | 0.460 |
Why?
|
| Facial Neoplasms | 4 | 2017 | 21 | 0.450 |
Why?
|
| Aged | 25 | 2025 | 21482 | 0.450 |
Why?
|
| Rhinoplasty | 2 | 2021 | 45 | 0.440 |
Why?
|
| Female | 43 | 2025 | 70787 | 0.420 |
Why?
|
| Cheek | 4 | 2017 | 25 | 0.420 |
Why?
|
| Needlestick Injuries | 2 | 2003 | 6 | 0.410 |
Why?
|
| Bandages | 2 | 2008 | 56 | 0.410 |
Why?
|
| Nose | 3 | 2022 | 102 | 0.400 |
Why?
|
| Colorectal Neoplasms | 2 | 2017 | 630 | 0.380 |
Why?
|
| Carcinoma | 1 | 2014 | 300 | 0.370 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 251 | 0.360 |
Why?
|
| Melanoma, Amelanotic | 1 | 2011 | 2 | 0.360 |
Why?
|
| Penile Neoplasms | 2 | 2002 | 36 | 0.360 |
Why?
|
| Toes | 2 | 2008 | 27 | 0.350 |
Why?
|
| Adult | 25 | 2024 | 31614 | 0.350 |
Why?
|
| Face | 3 | 2001 | 189 | 0.350 |
Why?
|
| Skin Diseases, Infectious | 2 | 2018 | 25 | 0.350 |
Why?
|
| Porokeratosis | 1 | 2010 | 2 | 0.350 |
Why?
|
| Cicatrix | 2 | 2022 | 121 | 0.340 |
Why?
|
| Nevus | 2 | 2016 | 35 | 0.340 |
Why?
|
| Antimetabolites | 1 | 2010 | 30 | 0.340 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1018 | 0.330 |
Why?
|
| Lacerations | 1 | 2010 | 33 | 0.330 |
Why?
|
| Surgical Instruments | 2 | 2008 | 57 | 0.330 |
Why?
|
| Nail Diseases | 4 | 2003 | 15 | 0.320 |
Why?
|
| Lung Neoplasms | 3 | 2017 | 1541 | 0.320 |
Why?
|
| Drug Eruptions | 2 | 2007 | 34 | 0.310 |
Why?
|
| Skin Transplantation | 2 | 2001 | 54 | 0.310 |
Why?
|
| Dermatitis, Irritant | 1 | 2009 | 4 | 0.310 |
Why?
|
| Pruritus | 2 | 2024 | 47 | 0.310 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2009 | 4 | 0.300 |
Why?
|
| Plants | 1 | 2009 | 47 | 0.300 |
Why?
|
| Ear Neoplasms | 2 | 2008 | 14 | 0.290 |
Why?
|
| Ear Auricle | 1 | 2008 | 4 | 0.290 |
Why?
|
| Case-Control Studies | 4 | 2024 | 3414 | 0.290 |
Why?
|
| Hair Diseases | 1 | 2008 | 12 | 0.280 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2008 | 12 | 0.280 |
Why?
|
| Epidermal Cyst | 1 | 2008 | 18 | 0.280 |
Why?
|
| Foreign-Body Reaction | 1 | 2008 | 16 | 0.280 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 280 | 0.280 |
Why?
|
| Dysplastic Nevus Syndrome | 2 | 2017 | 21 | 0.280 |
Why?
|
| Fingers | 1 | 2008 | 67 | 0.270 |
Why?
|
| Injections, Subcutaneous | 2 | 2025 | 126 | 0.270 |
Why?
|
| Xylans | 1 | 2006 | 4 | 0.250 |
Why?
|
| Hemangiopericytoma | 1 | 2006 | 9 | 0.250 |
Why?
|
| Organ Transplantation | 3 | 2004 | 180 | 0.230 |
Why?
|
| Carcinoma in Situ | 2 | 2002 | 74 | 0.230 |
Why?
|
| Acupuncture Therapy | 1 | 2024 | 13 | 0.230 |
Why?
|
| Complementary Therapies | 1 | 2024 | 42 | 0.220 |
Why?
|
| Mental Recall | 1 | 2025 | 143 | 0.210 |
Why?
|
| California | 1 | 2024 | 140 | 0.210 |
Why?
|
| Gloves, Surgical | 1 | 2003 | 4 | 0.210 |
Why?
|
| Needles | 1 | 2003 | 53 | 0.210 |
Why?
|
| Light | 1 | 2024 | 183 | 0.210 |
Why?
|
| Pain Measurement | 1 | 2025 | 352 | 0.200 |
Why?
|
| Interferon Inducers | 1 | 2002 | 6 | 0.200 |
Why?
|
| Delphi Technique | 1 | 2024 | 240 | 0.200 |
Why?
|
| Competitive Behavior | 1 | 2002 | 11 | 0.200 |
Why?
|
| Lentigo | 2 | 2000 | 2 | 0.190 |
Why?
|
| Paget Disease, Extramammary | 1 | 2002 | 4 | 0.190 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 53 | 0.190 |
Why?
|
| Risk Factors | 5 | 2024 | 10945 | 0.190 |
Why?
|
| Nose Deformities, Acquired | 1 | 2021 | 12 | 0.180 |
Why?
|
| Lip Neoplasms | 1 | 2021 | 4 | 0.180 |
Why?
|
| Lipodystrophy | 1 | 2001 | 33 | 0.180 |
Why?
|
| Fish Oils | 3 | 1992 | 80 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2003 | 155 | 0.180 |
Why?
|
| Muscle Neoplasms | 1 | 2021 | 21 | 0.180 |
Why?
|
| Lipoma | 1 | 2021 | 26 | 0.180 |
Why?
|
| Smoking | 2 | 2024 | 940 | 0.180 |
Why?
|
| Consensus | 1 | 2024 | 658 | 0.170 |
Why?
|
| Curettage | 1 | 2000 | 6 | 0.170 |
Why?
|
| Medicare | 1 | 2024 | 447 | 0.170 |
Why?
|
| Administration, Topical | 4 | 2007 | 140 | 0.170 |
Why?
|
| Pigmentation | 1 | 2020 | 36 | 0.170 |
Why?
|
| United States | 6 | 2024 | 11669 | 0.170 |
Why?
|
| Surgical Wound Infection | 1 | 2003 | 272 | 0.170 |
Why?
|
| Prevalence | 3 | 2024 | 2664 | 0.170 |
Why?
|
| Antifungal Agents | 3 | 1999 | 314 | 0.160 |
Why?
|
| Sulfonamides | 1 | 2002 | 283 | 0.160 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 724 | 0.160 |
Why?
|
| Inpatients | 1 | 2024 | 553 | 0.160 |
Why?
|
| Masks | 1 | 2020 | 40 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 127 | 0.160 |
Why?
|
| Hospital Mortality | 1 | 2024 | 1081 | 0.150 |
Why?
|
| Fellowships and Scholarships | 1 | 2002 | 325 | 0.150 |
Why?
|
| Dermatitis, Contact | 1 | 2018 | 7 | 0.150 |
Why?
|
| Hidradenitis Suppurativa | 1 | 1998 | 6 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2009 | 81 | 0.150 |
Why?
|
| Dermis | 1 | 2018 | 26 | 0.150 |
Why?
|
| Eczema | 1 | 2018 | 31 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 81 | 0.150 |
Why?
|
| Urticaria | 1 | 2018 | 22 | 0.150 |
Why?
|
| Epidermis | 1 | 2018 | 64 | 0.150 |
Why?
|
| Pigmentation Disorders | 1 | 1998 | 23 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 2 | 1999 | 305 | 0.150 |
Why?
|
| Aerospace Medicine | 1 | 2018 | 39 | 0.140 |
Why?
|
| Erythema | 4 | 1999 | 29 | 0.140 |
Why?
|
| Virus Activation | 1 | 2018 | 86 | 0.140 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 74 | 0.140 |
Why?
|
| Dermatitis, Atopic | 1 | 2018 | 47 | 0.140 |
Why?
|
| CREST Syndrome | 1 | 2017 | 4 | 0.140 |
Why?
|
| Peptides | 1 | 2001 | 844 | 0.140 |
Why?
|
| Public Health | 1 | 2020 | 280 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2001 | 382 | 0.140 |
Why?
|
| Collagen | 1 | 2018 | 303 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2014 | 175 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3761 | 0.130 |
Why?
|
| Bowen's Disease | 3 | 2009 | 4 | 0.130 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 49 | 0.130 |
Why?
|
| Prognosis | 6 | 2017 | 5016 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2017 | 376 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 3995 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1304 | 0.120 |
Why?
|
| Keratin-7 | 1 | 2014 | 8 | 0.110 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2014 | 13 | 0.110 |
Why?
|
| Shoulder | 2 | 2006 | 32 | 0.110 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2014 | 24 | 0.110 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 234 | 0.110 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 64 | 0.110 |
Why?
|
| Thyroidectomy | 1 | 2014 | 102 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 94 | 0.110 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 1718 | 0.110 |
Why?
|
| Hyperpigmentation | 2 | 2005 | 13 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 1829 | 0.100 |
Why?
|
| Sutures | 2 | 2008 | 69 | 0.100 |
Why?
|
| Microbiota | 1 | 2018 | 434 | 0.100 |
Why?
|
| Skin Pigmentation | 4 | 2001 | 29 | 0.100 |
Why?
|
| Margins of Excision | 3 | 2017 | 57 | 0.100 |
Why?
|
| Keratosis | 4 | 2007 | 17 | 0.100 |
Why?
|
| Telemedicine | 1 | 2018 | 506 | 0.090 |
Why?
|
| Barbering | 1 | 2011 | 1 | 0.090 |
Why?
|
| Stents | 1 | 1998 | 874 | 0.090 |
Why?
|
| Administration, Cutaneous | 2 | 2010 | 67 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2024 | 13027 | 0.090 |
Why?
|
| Time Factors | 2 | 2014 | 6451 | 0.090 |
Why?
|
| Desmin | 1 | 2010 | 20 | 0.080 |
Why?
|
| Surface Properties | 1 | 2010 | 93 | 0.080 |
Why?
|
| Pressure | 1 | 2010 | 131 | 0.080 |
Why?
|
| Myosin Heavy Chains | 1 | 2010 | 70 | 0.080 |
Why?
|
| Remission Induction | 1 | 2010 | 306 | 0.080 |
Why?
|
| Leg | 1 | 2010 | 134 | 0.080 |
Why?
|
| Nicotinic Acids | 1 | 2009 | 7 | 0.080 |
Why?
|
| Dermatitis, Occupational | 1 | 2009 | 2 | 0.080 |
Why?
|
| Patch Tests | 1 | 2009 | 7 | 0.080 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 10 | 0.080 |
Why?
|
| Ectoparasitic Infestations | 1 | 2008 | 8 | 0.080 |
Why?
|
| Siphonaptera | 1 | 2008 | 6 | 0.080 |
Why?
|
| Nevus, Pigmented | 2 | 2005 | 31 | 0.070 |
Why?
|
| Naphthalenes | 2 | 1999 | 38 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1285 | 0.070 |
Why?
|
| Actins | 1 | 2010 | 334 | 0.070 |
Why?
|
| Melanocytes | 2 | 2006 | 47 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 3358 | 0.070 |
Why?
|
| Travel | 1 | 2008 | 124 | 0.070 |
Why?
|
| Adolescent | 3 | 2024 | 20557 | 0.070 |
Why?
|
| Immunization | 1 | 2009 | 312 | 0.070 |
Why?
|
| Cheilitis | 1 | 2007 | 1 | 0.070 |
Why?
|
| Incidence | 4 | 2011 | 3376 | 0.070 |
Why?
|
| Ointments | 1 | 2007 | 13 | 0.070 |
Why?
|
| Mice, Hairless | 2 | 2002 | 30 | 0.070 |
Why?
|
| Dietary Fats | 1 | 1989 | 279 | 0.070 |
Why?
|
| Ankle | 1 | 2007 | 29 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 5410 | 0.070 |
Why?
|
| Recurrence | 2 | 2001 | 1453 | 0.060 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2005 | 1 | 0.060 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2005 | 6 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2008 | 187 | 0.060 |
Why?
|
| Idarubicin | 1 | 2005 | 8 | 0.060 |
Why?
|
| Histiocytosis, Sinus | 1 | 2006 | 34 | 0.060 |
Why?
|
| Hypothyroidism | 1 | 2006 | 78 | 0.060 |
Why?
|
| Surgical Equipment | 1 | 2004 | 5 | 0.060 |
Why?
|
| Allylamine | 2 | 1997 | 8 | 0.060 |
Why?
|
| Capsaicin | 1 | 2024 | 20 | 0.060 |
Why?
|
| Warts | 2 | 2003 | 17 | 0.060 |
Why?
|
| Mercaptopurine | 1 | 2005 | 72 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2014 | 2491 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 128 | 0.060 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 1987 | 156 | 0.050 |
Why?
|
| Dermatologic Agents | 2 | 2009 | 30 | 0.050 |
Why?
|
| Phototherapy | 1 | 2024 | 39 | 0.050 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2004 | 77 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 194 | 0.050 |
Why?
|
| Child | 1 | 2024 | 25783 | 0.050 |
Why?
|
| Patient Care Management | 1 | 2004 | 66 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 1671 | 0.050 |
Why?
|
| Equipment Failure | 1 | 2003 | 136 | 0.050 |
Why?
|
| Corynebacterium | 1 | 2003 | 12 | 0.050 |
Why?
|
| Aspergillus | 1 | 2003 | 26 | 0.050 |
Why?
|
| Mycobacterium | 1 | 2003 | 30 | 0.050 |
Why?
|
| Glomus Tumor | 1 | 2003 | 12 | 0.050 |
Why?
|
| Herpesvirus 1, Human | 1 | 2003 | 34 | 0.050 |
Why?
|
| Enterobacteriaceae | 1 | 2003 | 41 | 0.050 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2003 | 30 | 0.050 |
Why?
|
| Leishmania | 1 | 2003 | 35 | 0.050 |
Why?
|
| Internet | 1 | 2006 | 406 | 0.050 |
Why?
|
| Syringes | 1 | 2002 | 24 | 0.050 |
Why?
|
| Candida | 1 | 2003 | 84 | 0.050 |
Why?
|
| Celecoxib | 1 | 2002 | 32 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 445 | 0.050 |
Why?
|
| Operating Rooms | 1 | 2002 | 79 | 0.050 |
Why?
|
| Microsurgery | 1 | 2002 | 62 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2002 | 70 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2005 | 291 | 0.050 |
Why?
|
| Glatiramer Acetate | 1 | 2001 | 15 | 0.050 |
Why?
|
| Arm | 1 | 2002 | 77 | 0.050 |
Why?
|
| Probability | 1 | 2002 | 322 | 0.050 |
Why?
|
| Cryosurgery | 1 | 2002 | 49 | 0.040 |
Why?
|
| Scapula | 1 | 2021 | 15 | 0.040 |
Why?
|
| Random Allocation | 1 | 2002 | 431 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 437 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2009 | 3736 | 0.040 |
Why?
|
| Animals | 7 | 2008 | 34854 | 0.040 |
Why?
|
| Calibration | 1 | 2001 | 99 | 0.040 |
Why?
|
| Anus Neoplasms | 1 | 2001 | 41 | 0.040 |
Why?
|
| Dermatomycoses | 2 | 1991 | 18 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 673 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 3093 | 0.040 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 66 | 0.040 |
Why?
|
| Photography | 1 | 2001 | 86 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2002 | 223 | 0.040 |
Why?
|
| Documentation | 1 | 2001 | 121 | 0.040 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 1999 | 20 | 0.040 |
Why?
|
| Cyclin E | 1 | 1999 | 32 | 0.040 |
Why?
|
| Physical Examination | 1 | 2001 | 165 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 703 | 0.040 |
Why?
|
| Sex Factors | 2 | 2006 | 1354 | 0.040 |
Why?
|
| Benzylamines | 1 | 1999 | 19 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1249 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2002 | 329 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1161 | 0.040 |
Why?
|
| Dermatitis, Exfoliative | 1 | 1999 | 4 | 0.040 |
Why?
|
| Furunculosis | 1 | 1998 | 4 | 0.040 |
Why?
|
| Keratolytic Agents | 1 | 1998 | 6 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1999 | 64 | 0.040 |
Why?
|
| Clindamycin | 1 | 1998 | 41 | 0.040 |
Why?
|
| Isotretinoin | 1 | 1998 | 19 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2020 | 131 | 0.040 |
Why?
|
| Hair Follicle | 1 | 1998 | 35 | 0.040 |
Why?
|
| Equipment Design | 1 | 2000 | 600 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 462 | 0.040 |
Why?
|
| Mastic Resin | 1 | 1998 | 1 | 0.040 |
Why?
|
| Resins, Plant | 1 | 1998 | 3 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 451 | 0.040 |
Why?
|
| Neoplasms | 2 | 1995 | 2961 | 0.040 |
Why?
|
| Absorption | 1 | 1998 | 51 | 0.040 |
Why?
|
| Leukemic Infiltration | 1 | 1998 | 8 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1999 | 258 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2012 | 665 | 0.040 |
Why?
|
| Econazole | 1 | 1997 | 2 | 0.030 |
Why?
|
| Ketoconazole | 1 | 1997 | 10 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2003 | 541 | 0.030 |
Why?
|
| Epithelium | 1 | 1998 | 354 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2001 | 462 | 0.030 |
Why?
|
| Surgical Mesh | 1 | 1998 | 67 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 2139 | 0.030 |
Why?
|
| Retrospective Studies | 6 | 2016 | 17395 | 0.030 |
Why?
|
| Chemoprevention | 1 | 1997 | 53 | 0.030 |
Why?
|
| Tattooing | 1 | 1996 | 6 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 2002 | 571 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1999 | 491 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 1999 | 404 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1998 | 135 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1997 | 226 | 0.030 |
Why?
|
| Pyridones | 1 | 1997 | 130 | 0.030 |
Why?
|
| Immunocompromised Host | 2 | 1995 | 308 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 663 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 134 | 0.030 |
Why?
|
| Bites, Human | 1 | 1995 | 2 | 0.030 |
Why?
|
| Imidazoles | 1 | 1997 | 219 | 0.030 |
Why?
|
| Bites and Stings | 1 | 1995 | 27 | 0.030 |
Why?
|
| Cats | 1 | 1995 | 118 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 2002 | 875 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 1999 | 685 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1997 | 305 | 0.030 |
Why?
|
| Herpesviridae | 1 | 1995 | 34 | 0.030 |
Why?
|
| Disposable Equipment | 1 | 1994 | 18 | 0.030 |
Why?
|
| Hemostasis, Surgical | 1 | 1994 | 36 | 0.030 |
Why?
|
| Dogs | 1 | 1995 | 651 | 0.030 |
Why?
|
| Sunlight | 1 | 1994 | 26 | 0.030 |
Why?
|
| Pedigree | 1 | 1998 | 1724 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 2161 | 0.030 |
Why?
|
| Laser Therapy | 1 | 1996 | 232 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 1307 | 0.030 |
Why?
|
| Young Adult | 3 | 2016 | 9966 | 0.030 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1994 | 75 | 0.030 |
Why?
|
| Neoplasms, Basal Cell | 1 | 1993 | 8 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1577 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2002 | 1102 | 0.030 |
Why?
|
| DNA, Viral | 1 | 1995 | 492 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1997 | 1653 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 2 | 1995 | 131 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2001 | 1757 | 0.020 |
Why?
|
| Cysts | 1 | 1992 | 97 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 4690 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 1992 | 74 | 0.020 |
Why?
|
| Base Sequence | 1 | 1995 | 2900 | 0.020 |
Why?
|
| Mice | 3 | 2002 | 18509 | 0.020 |
Why?
|
| Health Surveys | 1 | 2011 | 260 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 956 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 2681 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1994 | 770 | 0.020 |
Why?
|
| Cryptococcosis | 1 | 1990 | 45 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2009 | 34 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3853 | 0.020 |
Why?
|
| Peace Corps | 1 | 2008 | 1 | 0.020 |
Why?
|
| Tanzania | 1 | 2008 | 74 | 0.020 |
Why?
|
| Hand | 1 | 2009 | 106 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1990 | 236 | 0.020 |
Why?
|
| Melanosis | 1 | 1987 | 10 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1294 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2196 | 0.020 |
Why?
|
| Mitoguazone | 1 | 1987 | 2 | 0.020 |
Why?
|
| Eflornithine | 1 | 1987 | 15 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2552 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2006 | 62 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2006 | 69 | 0.020 |
Why?
|
| Nucleoside Deaminases | 1 | 1985 | 26 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1177 | 0.020 |
Why?
|
| Parotid Neoplasms | 1 | 2005 | 17 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 1985 | 89 | 0.010 |
Why?
|
| Cytarabine | 1 | 2005 | 102 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 2005 | 81 | 0.010 |
Why?
|
| Leukemia | 1 | 1987 | 372 | 0.010 |
Why?
|
| Patient Care | 1 | 2004 | 99 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 313 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 511 | 0.010 |
Why?
|
| Texas | 1 | 2011 | 3632 | 0.010 |
Why?
|
| DNA Repair | 1 | 2006 | 567 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 364 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 373 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 1999 | 51 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1999 | 60 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2004 | 576 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 1999 | 113 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1999 | 86 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 2923 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1999 | 242 | 0.010 |
Why?
|
| Frozen Sections | 1 | 1998 | 31 | 0.010 |
Why?
|
| Ear, External | 1 | 1998 | 23 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 1999 | 285 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 1998 | 88 | 0.010 |
Why?
|
| Rabies | 1 | 1995 | 11 | 0.010 |
Why?
|
| Habits | 1 | 1995 | 25 | 0.010 |
Why?
|
| Dermatitis, Seborrheic | 1 | 1995 | 3 | 0.010 |
Why?
|
| Globins | 1 | 1995 | 27 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1995 | 32 | 0.010 |
Why?
|
| Connective Tissue Diseases | 1 | 1995 | 32 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1995 | 130 | 0.010 |
Why?
|
| India | 1 | 1995 | 238 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1995 | 128 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1995 | 225 | 0.010 |
Why?
|
| Alcoholism | 1 | 1995 | 250 | 0.010 |
Why?
|
| Trichophyton | 1 | 1991 | 1 | 0.010 |
Why?
|
| Foot Dermatoses | 1 | 1991 | 7 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 1555 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1991 | 197 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1990 | 153 | 0.000 |
Why?
|
| Leukotriene B4 | 1 | 1988 | 8 | 0.000 |
Why?
|
| Kidney Failure, Chronic | 1 | 1995 | 952 | 0.000 |
Why?
|
| Ornithine Decarboxylase | 1 | 1987 | 18 | 0.000 |
Why?
|
| Putrescine | 1 | 1987 | 11 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1995 | 926 | 0.000 |
Why?
|
| Polyamines | 1 | 1987 | 31 | 0.000 |
Why?
|
| Coformycin | 1 | 1985 | 7 | 0.000 |
Why?
|
| Pentostatin | 1 | 1985 | 11 | 0.000 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 1985 | 6 | 0.000 |
Why?
|
| Immunosorbent Techniques | 1 | 1985 | 25 | 0.000 |
Why?
|
| Isoelectric Focusing | 1 | 1985 | 23 | 0.000 |
Why?
|
| Half-Life | 1 | 1985 | 161 | 0.000 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1985 | 275 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1985 | 309 | 0.000 |
Why?
|
| Cell Division | 1 | 1987 | 744 | 0.000 |
Why?
|
| Gene Amplification | 1 | 1985 | 240 | 0.000 |
Why?
|
| Adenosine | 1 | 1985 | 135 | 0.000 |
Why?
|
| Kinetics | 1 | 1985 | 1130 | 0.000 |
Why?
|
| Diet | 1 | 1988 | 1125 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1987 | 3046 | 0.000 |
Why?
|
| Cell Line | 1 | 1985 | 2724 | 0.000 |
Why?
|
| Mutation | 1 | 1985 | 6250 | 0.000 |
Why?
|